Ebola -- Worldwide/Unknown
26 Jan 2017: Recombinant vesicular stomatitis virus vaccine elicits anti-Ebola seroconversion
[The Ebola virus outbreak of 2014 has prompted renewed interest in development of a vaccine that could be used for pre-exposure prophylaxis. This study tested the use of a rVSV [recombinant vesicular stomatitis virus] live attenuated recombinant virus vaccine that was genetically engineered to replace the VSV glycoprotein with that of the Zaire strain of Ebola virus (ZEBOV). The results of 2
Read more about it at HealthMap Global Disease Alerts via http://bit.ly/2jHAS2k
No comments:
Post a Comment